3 results
The primary objective is to examine the pharmacokinetics of Nanogam 100 mg/ml and compare these with Nanogam 50 mg/ml. The secondary objective is safety and tolerability of Nanogam 100 mg/ml. Aim is to show bioequivalency between Nanogam 50 mg/ml…
The primary objective of the study is to evaluate the safety and tolerability of the Occlutech® AFR device by assessing the incidence of SADEs in the 3 months following implantation. Secondary objectives are related to safety and efficacy:• To…
Primary objective1. To test the safety of cold plasma treatment: SAE in * 10% of participants, no pain (VAT * 2) and no local skin reaction: redness, blister formation, pain or itching. Secondary objectives:The effect of cold plasma treatment on : 1…